

# TEM-PCR Awards & Recognition



## Target Enriched Multiplex Polymerase Chain Reaction

- In 2006 **TEM-PCR** was awarded the runner up for the **Wall Street Journal Medical Technology Innovation of the Year Award**

---

- In 2006 **TEM-PCR** was awarded the **Frost and Sullivan Award for Technology Innovation and Leadership of the Year Award in Molecular Diagnostics in the European Union**

---

- In 2009 **DIATHERIX Laboratories** was awarded the **Technology Innovation Award for the First Commercially Available H1N1-09 test performed in a CLIA laboratory, made possible by TEM-PCR**

---

- In 2010 **Podiatry Today** listed **TEM-PCR** as one of its **Top Ten Innovations in Podiatric Care**. The only laboratory service to make the list.

**Tem-PCR is the first technology introduced to the clinical market that can identify multiple pathogens, both viral and bacterial, detect co-infections, identify specific toxin producing genes and determine highly transferable genetic drug resistances at the same time in one test panel.**

*DIATHERIX'S testing process, called Target Enriched Multiplex Polymerase Chain Reaction (Tem-PCR), uses molecular differential diagnostic (MDD) technology. Tem-PCR is the first test introduced to the clinical market that in a single result can identify multiple pathogens, both viral and bacterial; detect co-infections and determine their genetic drug resistance.*